| Registry | NCT06102252 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: none, treatment |
| Enrollment | 60 (Actual) |
| Sponsor | Sohag University (Other) |
| Conditions | Endometrial Carcinoma |
| Interventions | Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin (Drug) |
| Dates | start 2024-08-15, primary completion 2025-11-01, completion 2025-12-01, first posted 2023-10-26, last updated 2026-05-22 |
| Locations | 1 site in Egypt |
Related Papers Related Patents Related Grants Related Experts
All trials for Endometrial Carcinoma All trials of Paclitaxel/epirubcin/carboplatin All trials of Paclitaxel/carboplatin
Endometrial cancer, the most common gynecologic cancer worldwide, is steadily increasing in developed countries.The early-stage forms of endometrial cancer are usually highly curable by surgical treatment alone, whereas advanced stages require adjuvant interdictions such as radiotherapy and chemotherapy. Platinum and anthracycline drugs have long been used as standard adjuvant chemotherapy drugs for advanced and recurrent endometrial carcinomas. In one study, the standard combination adjuvant treatment with AP was found to be more effective as an adjuvant therapy than whole abdominal irradiation
| Arm | Type | Interventions | Description |
|---|---|---|---|
| group A | Active comparator | Drug: Paclitaxel/epirubcin/carboplatin | will receive the TEC regimen: paclitaxel 150mg/m2 infused for 3 hours, epirubicin 50mg/m2 infused for 30 minutes, and carboplatin 4mg/ml/min for one hour on day 1 every 3 weeks. |
| group B | Active comparator | Drug: Paclitaxel/carboplatin | ) will receive a ddTC regimen: paclitaxel 80mg/m2 for 3 hours on day 1,8,15. Carboplatin AUC 5 over one hour on day 1 repeated at 3-week intervals |
| group C | Active comparator | Drug: Paclitaxel/carboplatin | : paclitaxel 175 mg/m2 over 3 hours infusion on day 1-carboplatin AUC 5 over 1 hour on day 1 at 3 weeks intervals |
Sex: Female, ages: 20 Years to 70 Years, accepts healthy volunteers
Inclusion Criteria:• Age group: Histologically diagnosed with primary endometrial carcinoma
* more than 20 years old.
* Any histological type of endometrial carcinoma
* Stage III, IV
* Stage one I or II with one or more of the following factors:
1. Histologic grade 3 endometroid carcinoma with myometrial invasion still within half of the myometrium
2. histological grade 1,2 endometroid carcinomas with invasion of over half of myometrium
3. cervical stromal invasion
4. vascular invasion; or
5. serous carcinoma, clear cell carcinoma, or undifferentiated carcinoma
* performance status 0-2
* adequate function of all major organs
Exclusion Criteria:
* • Pt has received prior radiation or chemotherapy.
* Pt with sarcomatous component
* Metastatic endometrial carcinoma
* Other malignancy
* Unfit patient for chemotherapy| Facility | City | Country | Status |
|---|---|---|---|
| Sohag university Hospital | Sohag | Egypt |